January 13, 2011 Lexington, MA –- Concert Pharmaceuticals, Inc. announced the issuance of several new patents relating to specific compounds derived from its DCE Platform™ (Deuterated Chemical Entity Platform). U.S. Patents 7,855,204 and 7,820,666 specifically claim deuterium analogs of gefitinib and sitaglipin. In addition, Concert has over 90 issued or pending US and European patents on deuterated drug families.

“Selective deuterium modification can improve important drug properties, enabling us to obtain strong intellectual property protection for our novel compositions of matter in the US and abroad. ” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals.